Giorgio Silvestrelli
Research Subjects
Research Interests
Giorgio Silvestrelli has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- A. Lanari
Stroke Unit, Section of Neurology, C. Poma Hospital, Mantova, Italy
1 shared publication - Alessandra Giua
Clinica Neurologica, Università di Sassari
1 shared publication - Alessia Giossi
Department of Medical and Surgical Sciences, Neurological Clinic, University of Studies of Brescia, Brescia, Italy
1 shared publication - Alfonso Ciccone
S.C. di Neurologia e S.S. di Stroke Unit, ASST di Mantova, Italy (G.S., A. Ciccone)
1 shared publication - Andrea Baccarelli
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, USA
1 shared publication - Andrea Droghetti1 shared publication
Latest Publications
- 15 May 2019
- Published by Morressier GmbH
SAFETY AND SHORT-TERM EFFICACY OF VIDEOTHORACOSCOPIC EPICARDIAL LEFT ATRIAL APPENDAGE CLOSURE FOR THE PREVENTION OF CARDIOEMBOLISM
Background and Aims: Left atrial appendage closure (LAAC) has emerged as an alternative for stroke prevention in patients with Non-Valvular Atrial Fibrillation (NVAF) and contraindications to oral anticoagulation (OAC). Percutaneous LAAC with Watchman compared to warfarin in NVAF patients with increased stroke risk showed a significant reduction in hemorrhagic stroke and a similar
- 15 May 2019
- Published by Morressier GmbH
SAFETY AND SHORT-TERM EFFICACY OF VIDEOTHORACOSCOPIC EPICARDIAL LEFT ATRIAL APPENDAGE CLOSURE FOR THE PREVENTION OF CARDIOEMBOLISM
Background and Aims: Left atrial appendage closure (LAAC) has emerged as an alternative for stroke prevention in patients with Non-Valvular Atrial Fibrillation (NVAF) and contraindications to oral anticoagulation (OAC). Percutaneous LAAC with Watchman compared to warfarin in NVAF patients with increased stroke risk showed a significant reduction in hemorrhagic stroke and a similar
- Open Access
- 24 August 2012
- Published by MDPI AG in Neurology International
- Vol. 4 (2) , 44-48
Airborne Pollutants and Lacunar Stroke: A Case Cross-Over Analysis on Stroke Unit Admissions
Particulate air pollution is known to be associated with cardiovascular disease. The relation of particulate air pollution with cerebrovascular disease (CVD) has not been extensively studied, particularly in relation to different subtypes of stroke. A time-series study was conducted to evaluate the association between daily air pollution and acute stroke unit hospitalizations in Mantua, Italy. We analyzed 781 CVD consecutive patients living in Mantua county admitted between 2006-08. Data on stroke types, demographic variables, risk factors were available from the Lombardia Stroke Registry. Daily mean value of particulate matter with a diameter 10), carbon monoxide, nitric oxide, nitrogen dioxide, sulphur dioxide, benzene and ozone were used in the analysis. The association between CVD, ischemic strokes subtypes and pollutants was investigated with a case-crossover design, using conditional logistic regression analysis, adjusting for temperature, humidity, barometric pressure and holidays. Among the 781 subjects admitted 75.7% had ischemic stroke, 11.7% haemorrhagic stroke 12.6% transient ischemic attack. In men admission for stroke was associated with PM10 [odds ratio (OR) 1.01, 95%; confidence interval (CI) 1.00-1.02; P10 level registered on the day of admission for both genders (OR: 1.01, 95%; CI: 1.00-1.02; P<0.05) while for total anterior circulation syndrome stroke only in men (OR: 1.04, 95%; CI 1.01-1.07; P<0.05). In conclusion, our study confirms that air pollution peaks may contribute to increase the risk of hospitalization for stroke and particulate matter seems to be a significant risk factor, especially for lacunar stroke.
- 24 August 2012
- Published by MDPI AG in Neurology International
- Vol. 4 (2) , 44-48
Open AccessAirborne Pollutants and Lacunar Stroke: A Case Cross-Over Analysis on Stroke Unit Admissions
Particulate air pollution is known to be associated with cardiovascular disease. The relation of particulate air pollution with cerebrovascular disease (CVD) has not been extensively studied, particularly in relation to different subtypes of stroke. A time-series study was conducted to evaluate the association between daily air pollution and acute stroke unit hospitalizations in Mantua, Italy. We analyzed 781 CVD consecutive patients living in Mantua county admitted between 2006-08. Data on stroke types, demographic variables, risk factors were available from the Lombardia Stroke Registry. Daily mean value of particulate matter with a diameter 10), carbon monoxide, nitric oxide, nitrogen dioxide, sulphur dioxide, benzene and ozone were used in the analysis. The association between CVD, ischemic strokes subtypes and pollutants was investigated with a case-crossover design, using conditional logistic regression analysis, adjusting for temperature, humidity, barometric pressure and holidays. Among the 781 subjects admitted 75.7% had ischemic stroke, 11.7% haemorrhagic stroke 12.6% transient ischemic attack. In men admission for stroke was associated with PM10 [odds ratio (OR) 1.01, 95%; confidence interval (CI) 1.00-1.02; P10 level registered on the day of admission for both genders (OR: 1.01, 95%; CI: 1.00-1.02; P<0.05) while for total anterior circulation syndrome stroke only in men (OR: 1.04, 95%; CI 1.01-1.07; P<0.05). In conclusion, our study confirms that air pollution peaks may contribute to increase the risk of hospitalization for stroke and particulate matter seems to be a significant risk factor, especially for lacunar stroke.
- Open Access
- 6 July 2010
- Published by Bentham Science Publishers Ltd. in The Open Neurology Journal
- Vol. 4 (2) , 64-72
Clinical Pharmacology and Vascular Risk~!2009-05-11~!2009-12-22~!2010-06-14~!
Pharmacological treatment and several drugs of abuse have been associated with ischemic heart disease (IHD) and cerebrovascular diseases (CVD). However, there is a paucity of data on the independent risk of vascular disease (VD) associated with pharmacological treatment and no controlled trials demonstrating a reduction in risk with abstinence. Information about IHD and CVD-related drug abuse is mainly limited to epidemiological studies focused on urban populations. The potential link between some pharmacological treatments (estrogen, some oncologic drugs and some atypical antipsychotics) and cerebrovascular adverse events was analyzed, but disagreement about an association persists. Drugs of abuse, including cocaine, amphetamines and heroin, have been associated with an increased vascular risk. These drugs can cause abrupt changes in blood pressure, vasculitic-type changes, lead to embolization caused by infective endocarditis, and hemostatic and hematologic abnormalities that can result in increased blood viscosity and platelet aggregation. Long-term treatment strategies based on medication, psychological support, and outreach programs play an important role in treatment of drug dependency. In these last years public interest in risk factors for VD has been constantly increasing and the successful identification and management of pharmacological treatment and drug abuse can be challenging. One of the major public health issues for the future will be to focus more on new vascular risk factor recognition and management. The objective of this chapter is to review the relevance of IHD and CVD associated with various pharmacological treatments and drug abuse with focusing on ischemic disease. This chapter reports the clinical evidence of this association and analyzes the experimental role of new drugs as a growing risk factor of VD with the hypothetical new association. In conclusion, in this chapter great attention is paid to evaluating the scientific and real evidence of cerebrovascular effect and drug use and abuse so as to identify a new groups of "modifiable" risk factors.
- 6 July 2010
- Published by Bentham Science Publishers Ltd. in The Open Neurology Journal
- Vol. 4 (2) , 64-72
Open AccessClinical Pharmacology and Vascular Risk~!2009-05-11~!2009-12-22~!2010-06-14~!
Pharmacological treatment and several drugs of abuse have been associated with ischemic heart disease (IHD) and cerebrovascular diseases (CVD). However, there is a paucity of data on the independent risk of vascular disease (VD) associated with pharmacological treatment and no controlled trials demonstrating a reduction in risk with abstinence. Information about IHD and CVD-related drug abuse is mainly limited to epidemiological studies focused on urban populations. The potential link between some pharmacological treatments (estrogen, some oncologic drugs and some atypical antipsychotics) and cerebrovascular adverse events was analyzed, but disagreement about an association persists. Drugs of abuse, including cocaine, amphetamines and heroin, have been associated with an increased vascular risk. These drugs can cause abrupt changes in blood pressure, vasculitic-type changes, lead to embolization caused by infective endocarditis, and hemostatic and hematologic abnormalities that can result in increased blood viscosity and platelet aggregation. Long-term treatment strategies based on medication, psychological support, and outreach programs play an important role in treatment of drug dependency. In these last years public interest in risk factors for VD has been constantly increasing and the successful identification and management of pharmacological treatment and drug abuse can be challenging. One of the major public health issues for the future will be to focus more on new vascular risk factor recognition and management. The objective of this chapter is to review the relevance of IHD and CVD associated with various pharmacological treatments and drug abuse with focusing on ischemic disease. This chapter reports the clinical evidence of this association and analyzes the experimental role of new drugs as a growing risk factor of VD with the hypothetical new association. In conclusion, in this chapter great attention is paid to evaluating the scientific and real evidence of cerebrovascular effect and drug use and abuse so as to identify a new groups of "modifiable" risk factors.